← Leaderboards
Andrean Llewela Burnett
Iowa City Va Medical Center
$2,880,960
Attributed
$2,880,960
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $437.1K · FY2009–25$500K$375K$250K$125K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,880,960 · 3
VA$0 · 1
By mechanism
R01$2,319,250 · 2
K01$561,710 · 1
I01$0 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorHead And Neck Squamous Cell CarcinomaMediatingSignal TransductionBaseMouse ModelPathway InteractionsResponseAngiogenesisNeoplastic CellRecurrenceReceptor SignalingResistanceKineticsLaboratoriesPlayIn VitroChemotherapyLeadImmune ResponseEpidermal Growth Factor ReceptorIn VivoInflammatoryEpidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Grant awards (17)
IL-1-based immunotherapy in HNSCC$0
I01 · FY2025 · VA · contact PI
Inflammation and EGFR crosstalk in HNSCC Therapy$353,763
R01 · FY2024 · DE · contact PI
IL-1-based immunotherapy in HNSCC$0
I01 · FY2023 · VA · contact PI
IL-1-based immunotherapy in HNSCC$0
I01 · FY2022 · VA · contact PI
IL-1-based immunotherapy in HNSCC$0
I01 · FY2021 · VA · contact PI
IL-1-based immunotherapy in HNSCC$0
I01 · FY2020 · VA · contact PI
Role of inflammation in resistance to EGFR inhibitors in head and neck cancer$375,657
R01 · FY2018 · DE · contact PI
Role of inflammation in resistance to EGFR inhibitors in head and neck cancer$375,711
R01 · FY2017 · DE · contact PI
Role of inflammation in resistance to EGFR inhibitors in head and neck cancer$375,763
R01 · FY2016 · DE · contact PI
Role of inflammation in resistance to EGFR inhibitors in head and neck cancer$437,056
R01 · FY2015 · DE · contact PI
Role of inflammation in resistance to EGFR inhibitors in head and neck cancer$375,863
R01 · FY2014 · DE · contact PI
Role of inflammation in resistance to EGFR inhibitors in head and neck cancer$25,437
R01 · FY2014 · DE · contact PI
Use of 2-deoxy-D-glucose & PI3K/Akt pathway inhibitors in head & neck cancer ther$113,750
K01 · FY2013 · CA · contact PI
Use of 2-deoxy-D-glucose & PI3K/Akt pathway inhibitors in head & neck cancer ther$113,750
K01 · FY2012 · CA · contact PI
Use of 2-deoxy-D-glucose & PI3K/Akt pathway inhibitors in head & neck cancer ther$113,750
K01 · FY2011 · CA · contact PI
Use of 2-deoxy-D-glucose & PI3K/Akt pathway inhibitors in head & neck cancer ther$111,380
K01 · FY2010 · CA · contact PI
Use of 2-deoxy-D-glucose & PI3K/Akt pathway inhibitors in head & neck cancer ther$109,080
K01 · FY2009 · CA · contact PI